Inclusion Criteria:

- Written informed consent provided.

- Males or females aged ≥18 years.

- Able to comply with the required protocol and follow-up procedures, and able to
receive oral medications.

- Pathologically diagnosed of non-small cell lung cancer.

- Diagnosed as stage IIIA- N2.The diagnosis standard of N2 is as below: Pts with
resectable stage IIIA-N2 NSCLC confirmed by mediastinoscopy or EBUS or PET/CT.

- EGFR activating mutation in exon 19 or 21 by the biopsy of primary tumor or N2 lymph
node.

- Measurable disease must be characterized according to RECIST 1.1 criteria.

- Measurable lesions are defined as those that can be accurately measured in at least
one dimension (longest diameter to be recorded) as ≥ 10mm by spiral CT or MRI scan.
The measurable criteria of lymph node is the short axis ≥ 15 mm.

- ECOG performance status 0-1.

- Life expectancy ≥12 weeks.

- Adequate hematological function:Absolute neutrophil count (ANC) ≥1.5 x 109/L, and
Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or
exceed this level).

- Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal
(ULN);Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in
subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases.

- Adequate renal function:Serum creatinine ≤ 1.25 x ULN, and creatinine clearance ≥ 60
ml/min.

- Female subjects should not be pregnant or breast-feeding.

Exclusion Criteria:

- Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib,
gefitinib, cetuximab, trastuzumab).

- Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g.
monoclonal antibody therapy).

- Resection of primary malignancy.

- EGFR mutation (exon 19 or 21) negative or unknown.

- Uncontrolled central nervous system (CNS) metastasis.

- History of another malignancy in the last 5 years with the exception of the
following:Other malignancies cured by surgery alone and having a continuous
disease-free interval of 5 years are permitted; Cured basal cell carcinoma of the
skin and cured in situ carcinoma of the uterine cervix are permitted.

- Any unstable systemic disease (including active infection, uncontrolled hypertension,
unstable angina, congestive heart failure, myocardial infarction within the previous
year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic
disease).

- Known hypersensitivity to Tarceva or gemcitabine or cisplatin.

- Eye inflammation or eye infection not fully treated or conditions predisposing the
subject to this.

- Evidence of any other disease, neurological or metabolic dysfunction, physical
examination or laboratory finding giving reasonable suspicion of a disease or
condition that contraindicated the use of an investigational drug or puts the subject
at high risk for treatment-related complications.